Acumen Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Acumen Pharmaceuticals, Inc. (ABOS) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.50M, a 48.92% decline year-over-year.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$5.04M, a 8505.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $2.23M, a 46.56% increase year-over-year.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$3.90M, a 536.77% decline year-over-year.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $3.30M, a 10215.63% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $32.00K, a 98.89% decline from fiscal 2023.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $2.88M.
- Acumen Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$562.00K, a 116.11% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.54M 10-Q · filed 2026-08-12 | -$304.00K derived: sum of 3 quarters · filed 2026-08-12 | -$4.20M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$5.04M 10-Q · filed 2026-05-12 | -$2.81M derived: sum of 2 quarters · filed 2026-05-12 | -$6.70M derived: sum of 3 quarters · filed 2026-05-12 | -$1.80M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.66M derived: sum of 2 quarters · filed 2026-03-26 | $3.24M derived: sum of 3 quarters · filed 2026-08-12 | $3.30M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | -$3.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.01M derived: sum of 2 quarters · filed 2026-08-12 | $1.07M 10-Q · filed 2025-11-12 | $2.59M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.96M 10-Q · filed 2026-08-12 | $6.49M derived: sum of 3 quarters · filed 2026-08-12 | $7.38M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $60.00K 10-Q · filed 2026-05-12 | $1.58M derived: sum of 2 quarters · filed 2026-05-12 | $2.48M derived: sum of 3 quarters · filed 2026-05-12 | $3.63M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.42M derived: sum of 2 quarters · filed 2026-03-26 | $3.56M derived: sum of 3 quarters · filed 2026-03-26 | $32.00K 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $892.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.04M derived: sum of 2 quarters · filed 2025-11-12 | -$1.49M 10-Q · filed 2025-11-12 | -$1.41M 10-Q · filed 2024-11-12 | $1.57M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.38M 10-Q · filed 2025-08-12 | -$2.33M 10-Q · filed 2024-08-13 | $676.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.51M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$3.53M 10-Q · filed 2025-05-13 | -$3.51M 10-Q · filed 2024-05-14 | -$472.00K derived: sum of 2 quarters · filed 2025-05-13 | $359.00K derived: sum of 3 quarters · filed 2025-05-13 | -$51.00K derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.89M derived: sum of 2 quarters · filed 2025-03-27 | $3.48M derived: sum of 3 quarters · filed 2025-03-27 | $2.88M 10-K · filed 2025-03-27 | $2.99M 10-K · filed 2024-03-26 | |||
| 2023-09-30 | $831.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $421.00K derived: sum of 2 quarters · filed 2024-11-12 | -$182.00K 10-Q · filed 2024-11-12 | $318.00K derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$410.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.01M 10-Q · filed 2024-08-13 | -$513.00K derived: sum of 3 quarters · filed 2024-08-13 | -$143.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$603.00K 10-Q · filed 2024-05-14 | -$103.00K derived: sum of 2 quarters · filed 2024-05-14 | $267.00K derived: sum of 3 quarters · filed 2024-05-14 | $597.00K derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $870.00K derived: sum of 2 quarters · filed 2024-03-26 | $1.20M derived: sum of 3 quarters · filed 2024-03-26 | -$562.00K 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | $370.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $700.00K derived: sum of 2 quarters · filed 2023-11-13 | -$1.06M 10-Q · filed 2023-11-13 | $296.00K 10-Q · filed 2022-11-14 | $1.74M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.43M 10-Q · filed 2023-08-08 | -$984.00K 10-Q · filed 2022-08-15 | $1.37M derived: sum of 3 quarters · filed 2023-08-08 | $1.37M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | -$1.76M 10-Q · filed 2023-05-09 | -$1.48M 10-Q · filed 2022-05-16 | $1.04M derived: sum of 2 quarters · filed 2023-05-09 | $1.04M derived: sum of 3 quarters · filed 2023-05-09 | $773.00K derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $2.80M derived: sum of 2 quarters · filed 2023-03-27 | $2.54M derived: sum of 3 quarters · filed 2023-03-27 | $3.49M 10-K · filed 2023-03-27 | $3.64M 10-K · filed 2022-03-28 | |||
| 2021-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$269.00K derived: sum of 2 quarters · filed 2022-11-14 | $685.00K 10-Q · filed 2022-11-14 | -$168.00K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $691.00K 10-Q · filed 2022-08-15 | -$162.00K derived: sum of 3 quarters · filed 2022-08-15 | $425.00K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $954.00K 10-Q · filed 2022-05-16 | $101.00K derived: sum of 2 quarters · filed 2022-05-16 | $688.00K derived: sum of 3 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | -$853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$266.00K derived: sum of 2 quarters · filed 2022-03-28 | -$119.00K 10-K · filed 2022-03-28 | |||||
| 2020-09-30 | $587.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $734.00K 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $147.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |